Adipokines and the cardiorespiratory system in young patients with type 1 diabetes mellitus

Cover Page

Cite item

Full Text

Abstract

Early screening of complications of diabetes mellitus (DM) is one of the priorities for public health. Most patients with type 1 diabetes mellitus (T1DM) are patients of working age. New strategies for the primary prevention of cardiovascular disease (CVD) are needed to prevent their early disability.

Aim. To assess the predictive value of adipokines in relation to a personalized approach to the need for an in-depth examination of young patients with T1DM.

Materials and methods. The study included 98 patients without CVD: 70 patients with T1DM (mean age 26.4±8.1 years) and 28 patients without DM (mean age 27±9 years). All patients underwent a general clinical examination, the levels of adipokines were determined, ergospirometry, echocardiography, and bioimpedancemetry were performed.

Results. Changes in the cardiorespiratory system in patients with T1DM were revealed, in comparison with persons without T1DM: anaerobic threshold was reached faster (p=0.001), maximum oxygen consumption was lower (p=0.048), metabolic equivalent was reduced (p=0.0001). Signs of myocardial remodeling were found in the T1DM group: there was an increase in the relative wall thickness (p=0.001), the posterior wall of the left ventricle (p=0.001), myocardial mass index (p=0.049), in comparison with persons without T1DM. Changes in the adipokines system were revealed: higher levels of resistin (p=0.002) and visfatin (p=0.001), lower level of adiponectin (p=0.040) in T1DM. A positive correlation was found between posterior wall of the left ventricle and visfatin (p=0.014) and a negative relationship between adiponectin and relative wall thickness (p=0.018) in T1DM.

Conclusion. In T1DM, even at a young age, there are multifactorial changes in the heart, which can be detected even at the preclinical stage. The data obtained can be used to identify groups of patients at high risk of developing dangerous CVD in T1DM, which can form the basis for determining the timing of the start of preventive therapy.

About the authors

Oksana I. Vengrzhinovskaya

National Medical Research Center for Endocrinology

Author for correspondence.
Email: ksuyhap03@mail.ru
ORCID iD: 0000-0003-3370-8630

врач-эндокринолог

Russian Federation, Moscow

Irina Z. Bondarenko

National Medical Research Center for Endocrinology

Email: iz_bondarenko@mail.ru
ORCID iD: 0000-0002-5178-6029

д-р мед. наук, врач-кардиолог, гл. науч. сотр.

Russian Federation, Moscow

Olga A. Shatskaya

National Medical Research Center for Endocrinology

Email: shatskaya@bk.ru
ORCID iD: 0000-0003-1831-8052

канд. мед. наук, врач-эндокринолог, вед. науч. сотр.

Russian Federation, Moscow

larisa V. Nikankina

National Medical Research Center for Endocrinology

Email: larisa.nikankina@yandex.ru
ORCID iD: 0000-0002-3199-4998

канд. мед. наук, врач клинической лабораторной диагностики, и.о. зав. клинико-диагностической лаб.

Russian Federation, Moscow

Viktor Y. Kalashnikov

National Medical Research Center for Endocrinology

Email: victor9368@gmail.com
ORCID iD: 0000-0001-5573-0754

чл.-кор. РАН, д-р мед. наук, проф., зав. отд. кардиологии и сосудистой хирургии

Russian Federation, Moscow

Marina V. Shestakova

National Medical Research Center for Endocrinology

Email: Shestakova.Marina@endocrincentr.ru
ORCID iD: 0000-0003-3893-9972

акад. РАН, д-р мед. наук, проф., зав. каф. диабетологии и диетологии, дир. Института диабета, зам. дир.

Russian Federation, Moscow

Natalia G. Mokrysheva

National Medical Research Center for Endocrinology

Email: mokrisheva.natalia@endocrincentr.ru
ORCID iD: 0000-0002-9717-9742

чл.-кор. РАН, д-р мед. наук, проф., врач-эндокринолог, дир.

Russian Federation, Moscow

References

  1. Laukkanen JA, Kurl S, Lakka TA, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. J Am Coll Cardiol. 2001;38(1):72-9. doi: 10.1016/s0735-1097(01)01311-0
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический отчет по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13-41 [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus. 2017;20(1):13-41 (in Russian)]. doi: 10.14341/DM8664
  3. Balady GJ, Arena R, Sietsema K, et al; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191-225. doi: 10.1161/CIR.0b013e3181e52e69
  4. Всероссийское научное общество кардиологов. Прогнозирование и профилактика кардиальных осложнений внесердечных хирургических вмешательств. Национальные клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(6, приложение 3):1-28 [Russian Scientific Society of Cardiologists. Prediction and Prevention of Cardiac Complications of Noncardiac Surgical Interventions. National Clinical Guidelines. Kardiovaskulyarnaya terapiya i profilaktika. 2011;10(6, prilozhenie 3):1-28 (in Russian)].
  5. Rudski LG, Lai WW, Afilalo J, еt al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713. doi: 10.1016/j.echo.2010.05.010
  6. Парфенова Н.С., Танянский Д.А. Адипонектин: благоприятное воздействие на метаболические и сердечно-сосудистые нарушения. Артериальная гипертензия. 2013;19(1):84-96 [Parfenovа NS, Tanyanskiy DA. Adiponectin: beneficial effects on metabolic and cardiovascular dysfunctions. Arterialnaya Gipertenziya (Arterial Hypertension). 2013;19(1):84-96 (in Russian)]. doi: 10.18705/1607-419X-2013-19-1-84-96
  7. Вавилова Т.П., Плетень А.П., Михеев Р.К. Биологическая роль адипокинов как маркеров патологических состояний. Вопросы питания. 2017;86(2):5-13 [Vavilova TP, Pleten' AP, Mikheev RK. Biological role of adipokines and their association with morbid conditions. Voprosy pitaniia. 2017;86(2):5-13 (in Russian)]. doi: 10.1073/pnas.1920004117
  8. Bailey SD, Loredo-Osti JC, Lepage P, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes. 2006;55(10):2896-902. doi: 10.2337/db06-0189
  9. Гайворонский И.В., Ничипорук Г.И., Гайворонский И.Н., Ничипорук Н.Г. Биоимпедансометрия как метод оценки компонентного состава тела человека (обзор литературы) Вестник СПбГУ. Медицина. 2017;12(4):365-84 [Gaivoronsky IV, Nichiporuk GI, Gaivoronsky IN, Nichiporuk NG. Bioimpedansometry As A Method For Assessing The Component Composition Of The Human Body (Literature Review). Vestnik of Saint Petersburg University. Medicine. 2017;12(4):365-84 (in Russian)]. doi: 10.21638/11701/spbu11.2017.406
  10. Cho YH, Craig ME, Davis EA, et al; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial. Cardiac autonomic dysfunction is associated with high-risk albumin-to-creatinine ratio in young adolescents with type 1 diabetes in AdDIT (adolescent type 1 diabetes cardio-renal interventional trial). Diabetes Care. 2015;38(4):676-81. doi: 10.2337/dc14-1848
  11. Barstow TJ, Molé PA. Linear and nonlinear characteristics of oxygen uptake kinetics during heavy exercise. J Appl Physiol (1985). 1991;71(6):2099-106. doi: 10.1152/jappl.1991.71.6.2099
  12. Agostoni P, Cattadori G, Bussotti M, Apostolo A. Cardiopulmonary interaction in heart failure. Pulm Pharmacol Ther. 2007;20(2)130-4. doi: 10.1016/j.pupt.2006.03.001
  13. Alway SE, Mohamed JS, Myers MJ. Mitochondria Initiate and Regulate Sarcopenia. Exerc Sport Sci Rev. 2017;45(2):58-69. doi: 10.1249/JES.0000000000000101
  14. Муха Н.В., Говорин А.В., Зайцев Д.Н., Филев А.П. Структурно-функциональные нарушения миокарда и аритмии у больных сахарным диабетом 1 типа, осложненным кетоацидозом. Российский кардиологический журнал. 2020;25(7):3891 [Mukha NV, Govorin AV, Zaitsev DN, Filev AP. Structural and functional myocardial disorders and arrhythmias in patients with type 1 diabetes mellitus complicated by ketoacidosis. Russian Journal of Cardiology. 2020;25(7):3891. (in Russian)]. doi: 10.15829/1560-4071-2020-3891
  15. Acar G, Akcay A, Sokmen A, et al. Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus. J Am Soc Echocardiogr. 2009;22(6):732-8. doi: 10.1016/j.echo.2009.03.028
  16. Цветкова М.В., Хирманов В.Н., Зыбина Н.Н. Роль неэтерифицированных жирных кислот в патогенезе сердечно-сосудистых заболеваний. Артериальная гипертензия. 2010;16(1):93-103 [Tsvetkova MV, Khirmanov VN, Zybina NN. The role of nonesterified fatty acids in pathogenesis of cardiovascular disease. Arterial Hypertension. 2010;16(1):93-103 (in Russian)]. doi: 10.18705/1607-419X-2010-16-1-93-103
  17. Bando YK, Murohara T. Diabetes-related heart failure. Circ J. 2014;78(3):576-83. doi: 10.1253/circj.cj-13-1564
  18. Ouchi N, Ohishi M, Kihara S, et al. Fssociation of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231-4. doi: 10.1161/01.hyp.0000083488.67550.b8
  19. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an Independent Risk Factor for Hypertension. Hypertension. 2004;43:1318-23. doi: 10.1161/01.hyp.0000129281.03801.4b
  20. Вербовой А.Ф., Цанава И.А., Вербовая Н.И. Адипокины и метаболические показатели у больных сахарным диабетом 2 типа в сочетании с подагрой. Ожирение и метаболизм. 2016;13(1):20-4 [Verbovoy AF, Tsanava IA, Verbovaya NI. Adipokines and metabolie patients with type 2 diabetes mellitus in combination with gout. Ozhirenie i metabolism. 2016;13(1):20-4 (in Russian)]. doi: 10.14341/omet2016120-24
  21. Schnabel R, Messow CM, Lubos E, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J. 2008;29(5):649-57. doi: 10.1093/eurheartj/ehn009
  22. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways. Circulation. 2004;110(21):3335-40. doi: 10.1161/01.CIR.0000147825.97879.E7
  23. Теряева Н.Б. Адипокины: регуляция энергетического метаболизма и патогенез сердечно-сосудистых заболеваний. Креативная кардиология. 2007;1-2:20-5 [Teryaeva NB. Adiponectin: regulation of energymetabolism and the pathogenesis of cardiovascular diseases. Creative Cardiology. 2007;12:20-5 (in Russian)].
  24. Frankel DS, Vasan RS, D'Agostino RB, et al. Resistin, Adiponectin, and Risk of Heart Failure. J Am Coll Cardiol. 2009;53(9):754-62. doi: 10.1016/j.jacc.2008.07.073

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies